Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial

Omata, Masao; Nishiguchi, Shuhei; Ueno, Yoshiyuki; Mochizuki, Hitoshi; Izumi, Namiki; Ikeda, Fusao; Toyoda, Hidenori; Yokosuka, Osamu; Nirei, Kazushige; Genda, Takuya; Umemura, Takeji; Takehara, Tetsuo; Sakamoto, Naoya; Nishigaki, Yoichi; Nakane, Kunio; Toda, Nobuo; Ide, Tatsuya; Yanase, Mikio; Hino, Keisuke; Gao, Bing; L. Garrison, Kimberly; Dvory‐Sobol, Hadas; Ishizaki, Akinobu; Omote, Masa; M. Brainard, Diana; Knox, Steven; T. Symonds, William; G. McHutchison, John; Yatsuhashi, Hiroshi; Mizokami, Masashi

doi:10.1111/jvh.12312

Public

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial

Published in Journal of Viral Hepatitis • Sep 8, 2014

Authors:

Masao Omata

Shuhei Nishiguchi

Yoshiyuki Ueno

Abstract

Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV - peginterferon and ribavirin for 24 weeks - is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a ...

Subject

Sofosbuvir

Ribavirin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!